|
| UGT1A1*28基因多态性与复发性卵巢癌伊立替康化疗相关性的研究进展 |
|
| |
| DOI： |
| 中文关键词: 伊立替康 卵巢癌 UGT1A1 基因多态性 |
| 英文关键词: Irinotecan Ovarian cancer UGT1A1 Gene polymorphism |
| 基金项目: |
|
| 摘要点击次数: 418 |
| 全文下载次数: 0 |
| 中文摘要: |
| 伊立替康（CPT-11）联合铂类化疗广泛应用于复发性卵巢癌，尿苷二磷酸葡糖醛酸转移酶1A1（UGT1A1）在伊立替康的代谢中起重要作用，其功能、多态性与伊立替康的疗效和不良反应密切相关。本文作者从UGT1A1的功能和基因多态性、UGT1A1*28基因多态性与复发性卵巢癌伊立替康化疗的毒副作用及疗效进行综述，以指导复发性卵巢癌的个体化治疗。 |
| 英文摘要: |
| Irinotecan (CPT-11) combined with platinum-based chemotherapy is widely used in recurrent ovarian cancer. Uridine diphosphate glucuronyltransferase 1A1 (UGT1A1) plays an important role in the metabolism of irinotecan. Its function and polymorphism are closely related to the efficacy and adverse effects of irinotecan. This article reviews the functional and genetic polymorphisms of UGT1A1 and the relationship between UGT1A1*28 gene polymorphism and irinotecan-induced toxicity and efficacy for recurrent ovarian cancer,to guide the individualized treatment of recurrent ovarian cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
